A germline mutation is a genetic mutation that can be passed onto offspring, and there are germline mutations that could cause predisposition to pediatric nervous system cancers. Previous studies have shown that approximately 8% of patients with pediatric cancer had germline mutations and a high proportion of those patients had central nervous system tumors. This was especially true in patients with high-grade gliomas (HGG), atypical teratoid rhabdoid tumors (ATRT), SHH medulloblastomas, and retinoblastomas. Researchers will use data from the Pediatric Brain Tumor Atlas along with patient’s clinical data and family history to further study the impacts of predisposition to central nervous system tumors on patient outcomes. This information is important for both patients and their families who may share predisposition.
What are the goals of this project?
Researchers will use data collected across brain cancer types along with patient’s clinical data to study the impacts of cancer predisposition on patients with pediatric brain tumors.
What is the impact of this project?
Gaining information about the genetic predisposition to cancer of pediatric brain tumor patients is important for informing clinical care of individual patients and their family members who may share this predisposition.
Why is the CBTN request important to this project?
The Pediatric Brain Tumor Atlas has an unmatched breadth and depth of data concerning pediatric brain tumors that is integral to this research.
The Children's Brain Tumor Network contributed to this project by providing access to the Pediatric Brain Tumor Atlas.
Suzanne P. MacFarland, MD
Dr. MacFarland's research focuses on syndromes that predispose to cancer development in children and adolescents. She has initiated several individual and collaborative research projects, working in pediatric polyposis syndromes and Li-Fraumeni syndrome. She is uncovering novel genomic drivers of d
Children’s Hospital of Philadelphia
Miriam Bornhorst, MD
Brain tumors, Cancer genetics, Neurofibromatosis
Children’s National Hospital
Angela Waanders, MD, MPH
Specialties:Hematology, Oncology, Neuro-Oncology & Stem Cell TransplantationEducation: Tulane University School of Medicine, 2003Postgraduate Training: Fellowship in pediatric hematology/oncology, Children's Hospital of Philadelphia, 2006-2009; Residency is pediatrics, Children's Hospital of Philade
Ann & Robert H. Lurie Children’s Hospital of Chicago
Children’s Hospital of PhiladelphiaJoined on
Operations Center for the Children’s Brain Tumor Tissue Consortium, the Children’s Hospital of Philadelphia (CHOP) is currently ranked 1st nationally for their Pediatric Cancer Program by U.S. News & World Report. CHOP’s Biobank is home to the CBTTC’s pediatric brain and CNS tumor biorepository; the
Children’s National HospitalJoined on
Each year, the Brain Tumor Institute at Children’s National evaluates more than 100 new patients with brain tumors, and is recognized as a world leader in childhood brain tumor care and research. Children’s National has pioneered novel pediatric brain tumor therapies, including new molecularly-targe
Ann & Robert H. Lurie Children’s Hospital of ChicagoJoined on
Ann & Robert H. Lurie Children’s Hospital of Chicago treats 220 new patients each year with pediatric cancers. The hospital is ranked 17th in the nation for their pediatric oncology program and 11th for their neurology and neurosurgery program by U.S. News & World Report.Established in 1986, the Lur